Skip to contentA
Amphastar Pharmaceuticals, Inc.
A
AMPHAmphastar Pharmaceuticals, Inc. Q3 2017 · 10-Q
Revenue$57.92M$57.92M−9.8% vs Q3 2016 Net Income$99.00K$99.00K−97.5% vs Q3 2016 EPS Diluted$0.00$0.00−100.0% vs Q3 2016 Gross Profit$20,553,000−25.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR
Operating Cash Flowderived$2,472,000+90.4% Free Cash Flowderived-$8,941,000N/M Margins · derivedGross margin35.5%−7.5 pt vs Q3 2016
Operating margin-5.1%−14.1 pt vs Q3 2016
Net margin0.2%−5.9 pt vs Q3 2016
ended Sep 30, 2017 · filed Nov 9, 2017 · 40 d after period end